-
Something wrong with this record ?
The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma
M. Cechova, M. Chocholaty, T. Zima, M. Babjuk, M. Kalousova,
Language English Country Greece
Document type Journal Article
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
- MeSH
- Time Factors MeSH
- Progression-Free Survival MeSH
- Carcinoma, Renal Cell blood mortality secondary surgery MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local MeSH
- Biomarkers, Tumor blood MeSH
- Kidney Neoplasms blood mortality pathology surgery MeSH
- Nephrectomy MeSH
- Disease Progression MeSH
- Prospective Studies MeSH
- Risk Factors MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Pregnancy-Associated Plasma Protein-A metabolism MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND/AIM: Proteinase pregnancy-associated plasma protein A (PAPP-A) modulates the cell growth and carcinogenesis process. Its role in clear cell renal cell carcinoma (ccRCC) remains unclear. This study aimed to evaluate the significance of PAPP-A serum concentration in diagnosis, follow-up and prognosis of ccRCC patients. MATERIALS AND METHODS: In a prospective study including 121 patients who underwent radical or partial nephrectomy for ccRCC [localized ccRCC without relapse (n=80), localized ccRCC with later relapse (n=26), primary metastatic cancer (n=15)] PAPP-A serum concentration was assessed preoperatively and in certain subgroups also postoperatively. RESULTS: PAPP-A serum concentration showed no statistically significant difference between ccRCC and controls and among ccRCC subgroups, respectively. Disease stage and Fuhrman's grade were not shown to affect PAPP-A concentration. The dynamics of postoperative PAPP-A concentrations did not reveal any significance and PAPP-A was not a prognostic factor for cancer related or overall survival. CONCLUSION: PAPP-A serum concentration does not seem to be a useful biomarker in ccRCC.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19027601
- 003
- CZ-PrNML
- 005
- 20190816101950.0
- 007
- ta
- 008
- 190813s2019 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/anticanres.13466 $2 doi
- 035 __
- $a (PubMed)31177175
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Cechova, Marcela $u Department of Urology, University Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 14
- $a The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma / $c M. Cechova, M. Chocholaty, T. Zima, M. Babjuk, M. Kalousova,
- 520 9_
- $a BACKGROUND/AIM: Proteinase pregnancy-associated plasma protein A (PAPP-A) modulates the cell growth and carcinogenesis process. Its role in clear cell renal cell carcinoma (ccRCC) remains unclear. This study aimed to evaluate the significance of PAPP-A serum concentration in diagnosis, follow-up and prognosis of ccRCC patients. MATERIALS AND METHODS: In a prospective study including 121 patients who underwent radical or partial nephrectomy for ccRCC [localized ccRCC without relapse (n=80), localized ccRCC with later relapse (n=26), primary metastatic cancer (n=15)] PAPP-A serum concentration was assessed preoperatively and in certain subgroups also postoperatively. RESULTS: PAPP-A serum concentration showed no statistically significant difference between ccRCC and controls and among ccRCC subgroups, respectively. Disease stage and Fuhrman's grade were not shown to affect PAPP-A concentration. The dynamics of postoperative PAPP-A concentrations did not reveal any significance and PAPP-A was not a prognostic factor for cancer related or overall survival. CONCLUSION: PAPP-A serum concentration does not seem to be a useful biomarker in ccRCC.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 650 _2
- $a karcinom z renálních buněk $x krev $x mortalita $x sekundární $x chirurgie $7 D002292
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory ledvin $x krev $x mortalita $x patologie $x chirurgie $7 D007680
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 _2
- $a nefrektomie $7 D009392
- 650 _2
- $a těhotenský plazmatický protein A $x metabolismus $7 D011266
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Chocholaty, Matus $u Department of Urology, University Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Zima, Tomas $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Babjuk, Marek $u Department of Urology, University Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Kalousova, Marta $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic marta.kalousova@lf1.cuni.cz.
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 39, č. 6 (2019), s. 3249-3253
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31177175 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190816102219 $b ABA008
- 999 __
- $a ok $b bmc $g 1432750 $s 1066061
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 39 $c 6 $d 3249-3253 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20190813
